|
 Antibody levels in people receiving Sinopharm's BBIBP-CorV vaccine
had a 1.38-fold reduction to the Delta variant versus an older
version of the coronavirus first identified in Wuhan, a lab study
based on samples from people in Sri Lanka showed. https://bit.ly/3hTjzJt
The study was conducted by scientists from University of Sri
Jayewardenepura as well as Colombo Municipal Council in Sri Lanka,
and University of Oxford in the United Kingdom.
The Delta variant, first found in India late last year, has since
become the dominant version of the virus worldwide and is behind a
recent surge in infections reported in many countries including
Britain, Indonesia, the United States and South Korea. It has been
detected in more than 90 nations worldwide.
The vaccine from Sinopharm, formally China National Pharmaceutical
Group, also showed a more pronounced 10-fold decrease in antibody
levels to the Beta variant, first found in South Africa, the study,
published on Monday ahead of peer review, showed.
[to top of second column] |
 Researchers said they found no
significant difference in levels of antibodies
to the two variants from blood serum of
vaccinated people compared with the serum of
those who had been naturally infected.
This suggested that Sinopharm's vaccine may be
able to induce antibody-based responses against
the two variants similar to the levels seen
following natural infection, the paper said.
The two-dose vaccine is one of the most widely
used COVID-19 shots in China, and Sinopharm
agreed to provide up to 170 million doses to the
global vaccine sharing scheme COVAX through to
the middle of 2022.
(Reporting by Roxanne Liu and Ryan Woo; Editing
by Miyoung Kim and Jane Merriman)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
